Progress on novel immunomodulatory agents for HIV-1 infection and other infectious diseases

Expert Opinion on Therapeutic Patents

Volumn 13, Issue 6, 2003, Pages 867-882

  Masihi, K Noel ^a  

^a ROBERT KOCH INSTITUTE   (Germany)

Author keywords

Chemokine; Chemokine inhibitor; Cytokine; Hepatitis virus; HIV; Immunomodulators; Interferons

Indexed keywords

1 (2 BROMOPHENYL) 3 (2 HYDROXY 4 NITROPHENYL)UREA; ALPHA TOCOPHEROL DERIVATIVE; AMIDE; ANILINE DERIVATIVE; CHEMOKINE; CHEMOKINE RECEPTOR; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR4; ENFUVIRTIDE; HETEROCYCLIC COMPOUND; IMMUNOMODULATING AGENT; PEPTIDE DERIVATIVE; PEPTIDE T; PERTUSSIS TOXIN; PIPERIDINE DERIVATIVE; PYRROLIDINE DERIVATIVE; RANTES; RANTES DERIVATIVE; RECEPTOR BLOCKING AGENT; RECOMBINANT COLONY STIMULATING FACTOR; RECOMBINANT CYTOKINE; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; RECOMBINANT INTERFERON; RECOMBINANT INTERLEUKIN 2; T 140; UNCLASSIFIED DRUG; UNINDEXED DRUG; VIRUS RECEPTOR;

CELL INVASION; CLINICAL PRACTICE; COMBINATION CHEMOTHERAPY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG RESEARCH; DRUG STRUCTURE; DRUG TARGETING; DRUG USE; HEPATITIS B; HEPATITIS C; HOST CELL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFLAMMATORY DISEASE; LICENCE; MOUSE; NONHUMAN; PHARMACEUTICAL ENGINEERING; PROTEIN FUNCTION; REVIEW; VIRUS INFECTION;

EID: 0037633162     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543776.13.6.867     Document Type: Review

References (81)

1. KSIAZEK TG, ERDMAN D, GOLDSMITH C et al.: The SARS: a novel coronavirus associated with severe acute respiratory syndrome. N. Engl. J. Med. (2003) NEJMoa030781.
2. AMYES SGB: The rise in bacterial resistance is partly because there have been no new classes of antibiotics since the 1960s. Br. Med. J. (2000) 320:199-200.
3. TAYLOR PW, STAPLETON PD, PAUL LJ: New ways to treat bacterial infections. Drug Discov. Today (2002) 7:1086-1091.
4. MCGUIRK P, MILLS KHG: Pathogen-specific regulatory T cells provoke a shift in the Th1/Th2 paradigm in immunity to infectious diseases. Trends in Immunology (2002) 23:450-455.
5. MASIHI KN: Fighting infection using immunomodulatory agents. Expert. Opin. Biol. Ther. (2001) 1:641-653.
6. MASIHI KN: Immunomodulatory agents for prophylaxis and therapy of infections. Int. J. Antimicrobial Agents (2000) 14:181-191.
7. HENGEL H, MASIHI KN: Combinatorial immunotherapies for infectious diseases. Int. Immunopharmacol. (2003) 3:1-9.
8. HORUK R: Chemokine receptors. Cytokine & Growth Factor Reviews (2001) 12:313-335.
9. + T cell help in immunity to HIV. Vaccine (2002) 20:1961-1963.
10. AQUARO S, CALIO R, BALZARINI J, BELLOCCHI MC, GARACI E, PERNO CF: Macrophages and HIV infection: therapeutical approaches toward this strategic virus reservoir. Antiviral Res. (2002) 55:209-225.
11. CHINEN J, SHEARER WT: Molecular virology and immunology of HIV infection. J. Allergy Clin. Immunol. (2002) 110:189-198.
12. BERGER EA, MURPHY PM, FARBER JM: Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease. Ann. Rev. Immunol. (1999) 17:657-700.
13. NANSEN A, CHRISTENSEN JP, ANDREASEN SO, BARTHOLDY C, CHRISTENSEN JE, THOMSEN AR: The role of CC chemokine receptor 5 in antiviral immunity. Blood (2002) 99:1237-1245.
14. DRAGIC T: An overview of the determinants of CCR5 and CXCR4 co-receptor function. J. Gen. Virol. (2001) 82:1807-1814.
15. DENG H, LIU R, ELLMEIER W, CHOE S et al.: Identification of a major co-receptor for primary isolates of HIV-1. Nature (1996) 381:661-666.
16. LEHNER T: The role of CCR5 chemokine ligands and antibodies to CCR5 coreceptors in preventing HIV infection. Trends Immunol. (2002) 23:347-351.
17. KAZMIERSKI WM, BOONE L, LAWRENCE W, WATSON C, KENAKIN T: CCR5 chemokine receptors: gatekeepers of HIV-1 infection. Curr. Drug Targets. Infect. Disord. (2002) 2:265-278.
18. BLANPAIN C, LIBERT F, VASSART G, PARMENTIER M: CCR5 and HIV infection. Receptors Channels (2002) 8:19-31.
19. ALKHATIB G, COMBADIERE C, BRODER CC et al.: CC CKR5: a RANTES, MIP-1α, MIP-1β receptor as a fusion cofactor for macrophage-tropic HIV-1. Science (1996) 272:1955-1958.
20. WETZEL MA, STEELE AD, HENDERSON EE, ROGERS TJ: The effect of X4 and R5 HIV-1 on C, CC, and CXC chemokines during the early stages of infection in human PBMCs. Virology (2002) 292:6-15.
21. FERNANDEZ EJ, LOLIS E: Structure, function, and inhibition of chemokines. Ann. Rev. Pharmacol. Toxicol. (2002) 42:469-499.
22. PANI A, LOI AG, MURA M, MARCEDDU T, LA COLLA P, MARONGIU ME: Targeting HIV: old and new players. Curr. Drug Targets Infect. Disord (2002) 2:17-32.
23. LUSSO P: HIV and chemokines: implications for therapy and vaccine. Vaccine (2002) 20:1964-1967.
24. SCOZZAFAVA A, MASTROLORENZO A, SUPURAN CT: Non-peptidic chemokine receptors antagonists as emerging anti-HIV agents. J. Enzyme Inhib. Med. Chem. (2002) 17:69-76.
25. VERANI A, LUSSO P: Chemokines as natural HIV antagonists. Curr. Mol. Med. (2002) 2:691-702.
26. PROUDFOOT AEI, POWER CA, ROMMEL C, WELLS TNC: Strategies for chemokine antagonists as therapeutics. Semin. Immunol (2003) 15(1):57-65.
27. REGOES RR, BONHOEFFER SEBA: HIV coreceptor usage and drug treatment. J. Theor. Biol. (2002) 217:443-457.
28. ONUFFER JJ, HORUK R: Chemokines, chemokine receptors and small-molecule antagonists: recent developments. Trends Pharmacol. Sci. (2002) 23:459-467.
29. ALFANO M, SCHMIDTMAYEROVA H, AMELLA CA, PUSHKARSKY T, BUKRINSKY M: The B-oligomer of pertussis toxin deactivates CC chemokine receptor 5 and blocks entry of M-tropic HIV-1 strains. J. Exp. Med. (1999) 190:597-605.
30. RICHARDSON RM, TOKUNAGA K, MARJORAM R, SATA T, SNYDERMAN R. Interleukin-8-mediated heterologous receptor internalization provides resistance to HIV-1 infectivity: role of signal strength and receptor desensitization. J. Biol. Chem. (2003) 278(18):15867-15873.
31. LANE BR, STRIETER RM, COFFEY MJ, MARKOVITZ DM: Human immunodeficiency virus Type 1 (HIV-1)-induced GRO-α production stimulates HIV-1 replication in macrophages and T lymphocytes. J. Virol. (2001) 75:5812-5822.
32. LANE BR, LORE K, BOCK PJ et al.: Interleukin-8 stimulates human immunodeficiency virus Type 1 replication and is a potential new target for antiretroviral therapy. J. Virol. (2001) 75:8195-8202.
33. RUFF MR, MELENDEZ-GUERRERO LM, YANG Qe et al.: Peptide T inhibits HIV-1 infection mediated by the chemokine receptor-5 (CCR5). Antiviral Res. (2001) 52:63-75. Pls check prime conv.ty
34. TAMAMURA H, HIRAMATSU K, MIYAMOTO K et al.: Synthesis and evaluation of pseudopeptide analogues of a specific CXCR4 inhibitor, T140: the insertion of an (E)-alkene dipeptide isostere into the [β]II′-turn moiety. Bioorg. Med. Chem. Lett. (2002) 12:923-928.
35. STRIZKI JM, XU S, WAGNER NE et al.: SCH-C (SCH 351125), an orally bioavailable, small molecule antagonist of the chemokine receptor CCR5, is a potent inhibitor of HIV-1 infection in vitro and in vivo. PNAS (2001) 98:12718-12723.
36. TRKOLA A, KUHMANN SE, STRIZKI JM et al.: HIV-1 escape from a small molecule, CCR5-specific entry inhibitor does not involve CXCR4 use. PNAS (2002) 99:395-400.
37. VICENZI E, ALFANO M, GHEZZI S et al.: Divergent regulation of HIV-1 replication in PBMC of infected individuals by CC chemokines: suppression by RANTES, MIP-1α, and MCP-3, and enhancement by MCP-1. J. Leukoc. Biol. (2000) 68:405-412.
38. LUSSO P: HIV and chemokines: implications for therapy and vaccine. Vaccine (2002) 20:1964-1967.
39. POLO S, NARDESE V, DE SANTIS C et al.: Enhancement of the HIV-1 inhibitory activity of RANTES by modification of the N-terminal region: dissociation from CCR5 activation. Eur. J. Immunol. (2000) 30:3190-3198.
40. RUSCONI S, LA SETA C, CITTERIO P et al.: Combination of CCR5 and CXCR4 inhibitors in therapy of human immunodeficiency virus Type 1 infection: in vitro studies of mixed virus infections. J. Virol. (2000) 74:9328-9332.
41. MENTEN P, WUYTS A, VAN DAMME J: Macrophage inflammatory protein-1. Cytokine Growth Factor Rev. (2002) 13:455-481.
42. PINTO LA, WILLIAMS MS, DOLAN MJ, HENKART PA, SHEARER GM: β-chemokines inhibit activation-induced death of lymphocytes from HIV-infected individuals. Eur. J. Immunol. (2000) 30:2048-2055.
43. LEHRER RI, GANZ T: Defensins of vertebrate animals. Curr. Opin. Immunol. (2002) 14:96-102.
44. . RAJ PA, DENTINO AR: Current status of defensins and their role in innate and adaptive immunity. FEMS Microbiology Letters (2002) 206:9-18.
45. ZHANG L, YU W, HE T et al.: Contribution of human α-defensin 1, 2, and 3 to the anti-HIV-1 activity of CD8 antiviral factor. Science (2002) 298:995-1000.
46. NAKASHIMA H, YAMAMOTO N, MASUDA M, FUJII N: Defensins inhibit HIV replication in vitro. AIDS (1993) 7(8):1129.
47. MONELL CR, STRAND M: Structural and functional similarities between synthetic HIV gp41 peptides and defensins. Clin. Immunol. Immunopathol. (1994) 71:315-324.
48. COLE AM, HONG T, BOO LM et al.: Retrocyclin: a primate peptide that protects cells from infection by T- and M-tropic strains of HIV-1. Proc. Natl. Acad. Sci. USA (2002) 99:1813-1818.
49. BIRAGYN A, BELYAKOV IM, CHOW YH, DIMITROV DS, BERZOFSKY JA, KWAK LW: DNA vaccines encoding human immunodeficiency virus-1 glycoprotein 120 fusions with proinflammatory chemoattractants induce systemic and mucosal immune responses. Blood (2002) 100:1153-1159.
50. COLE AM, LIAO HI, GANZ T, YANG OO: Antibacterial activity of peptides derived from envelope glycoproteins of HIV-1. FEBS Lett. [In Press]
51. ARTHOS J, CICALA C, STEENBEKE TD et al.: Biochemical and biological characterization of a dodecameric CD4-Ig fusion protein: implications for therapeutic and vaccine strategies. J. Biol. Chem. (2002) 277:11456-11464.
52. JACOBSON JM, LOWY I, FLETCHER CV et al.: Single-dose safety, pharmacology, and antiviral activity of the human immunodeficiency virus (HIV) Type 1 entry inhibitor PRO 542 in HIV-infected adults. J. Infect. Dis. (2000) 182:326-329.
53. PITRAK DL: Filgrastim treatment of HIV-infected patients improves neutrophil function. AIDS (1999) 13(Suppl.2):S25-S30.
54. WELCH W, FOOTE M: The use of filgrastim in AIDS-related neutropenia. J. Hematother. Stem. Cell Res. (1999) 8(Suppl.1):S9-S16.
55. DAVIDSON M, MIN YI, HOLBROOK JT et al.: Influence of filgrastim (granulocyte colony-stimulating factor) on human immunodeficiency virus Type 1 RNA in patients with cytomegalovirus retinitis. J. Infect. Dis. (2002) 186:1013-1018.
56. KURITZKES DR: Clinical experience with filgrastim in AIDS. J. Hematother. Stem Cell Res. (1999) 8(Suppl.1):S17-S19.
57. NIELSEN SD, SORENSEN TU, ALADDIN H et al.: The effect of long-term treatment with granulocyte colony-stimulating factor on hematopoiesis in HIV-infected individuals. Scand. J. Immunol. (2000) 52:298-303.
58. DUBREUIL-LEMAIRE ML, GORI A, VITTECOQ D et al.: Lenograstim for the treatment of neutropenia in patients receiving ganciclovir for cytomegalovirus infection: a randomised, placebo-controlled trial in AIDS patients. Eur. J. Haematol. (2000) 65:337-343.
59. ARMSTRONG WS, KAZANJIAN P: Use of cytokines in human immunodeficiency virus-infected patients: colony-stimulating factors, erythropoietin, and interleukin-2. Clin. Infect. Dis. (2001) 32:766-773.
60. IMAMI N, HARDY G, GOTCH F: Development of immunotherapeutic strategies for HIV-1. Expert. Opin. Biol. Ther (2001) 1:803-816.
61. PAU AK, TAVEL JA: Therapeutic use of interleukin-2 in HIV-infected patients. Curr. Opin. Pharmacol. (2001) 1:803-816.
62. TAMBUSSI G, GHEZZI S, NOZZA S et al.: Efficacy of low-dose intermittent subcutaneous interleukin (IL)-2 in antiviral drug-experienced human immunodeficiency virus-infected persons with detectable virus load: a controlled study of 3 IL-2 regimens with antiviral drug therapy. J. Infect. Dis. (2001) 183:1476-1484.
63. + T lymphocyte expansion. Clin. Immunol. (2001) 99:30-42.
64. IMAMI N, HARDY G, BURTON C et al.: Immune responses and reconstitution in HIV-1 infected individuals: impact of anti-retroviral therapy, cytokines and therapeutic vaccination. Immunol. Lett. (2001) 79:63-76.
65. SCHAEFER M, ENGELBRECHTA MA, GUT O et al: Interferon α (IFN [α]) and psychiatric syndromes: a review. Prog. Neuropsychopharmacol Biol. Psychiatry (2002) 26:731-746.
66. KOLIOUSKAS D, SIDIROPOULOS I, MASMANIDOU M, DOKAS S, ZIAKAS A: Comparative analysis of Peg-interferon α-2b and lamivudine in the treatment of chronic hepatitis B patients: preliminary results. J. Hepatol. (2002) 36:237-238.
67. SANTANTONIO T, ANNA N, SINISI E et al.: Lamivudine/interferon combination therapy in anti-HBe positive chronic hepatitis B patients: a controlled pilot study. J. Hepatol. (2002) 36:799-804.
68. SHAD JA, MCHUTCHISON JG: Current and future therapies of hepatitis C. Clin. Liver Dis. (2001) 5:335-359.
69. PIMSTONE NR, CANIO JB, CHIANG MH: Ribavirin/interferon-2b therapy is very effective in the treatment of chronic hepatitis C genotype 2 and 3 patients who have failed to respond virologically to IFN monotherapy. (2001) 120:A-382.
70. LUXON BA, GRACE M, BRASSARD D, BORDENS R: Pegylated interferons for the treatment of chronic hepatitis C infection. Clin. Ther. (2002) 24:1363-1383.
71. RAJENDER R, MODI MW, PEDDER S: Use of peginterferon α-2a (40 kDa) (Pegasys(R)) for the treatment of hepatitis C. Adv. Drug Delivery Rev. (2002) 54:571-586.
72. BILLICH A: Thymosin α1. SciClone Pharmaceuticals. Curr. Opin. Investig. Drugs (2002) 3:698-707.
73. SUGAHARA S, ICHIDA T, YAMAGIWA S et al.: Thymosin-[α]1 increases intrahepatic NKT cells and CTLs in patients with chronic hepatitis B. Hepatol. Res. (2002) 24:346-354.
74. ROTHENFUSSER S, TUMA E, ENDRES S, HARTMANN G: Plasmacytoid dendritic cells: the key to CpG. Hum. Immunol. (2002) 24:346-354.
75. AKIRA S, HEMMI H: Recognition of pathogen-associated molecular patterns by TLR family. Immunol. Lett. (2002) 24:346-354.
76. SAUDER DN: Immunomodulatory and pharmacologic properties of imiquimod. J. Am. Acad. Dermatol. (2000) 43:S6-S11.
77. STANLEY MA: Imiquimod and the imidazoquinolones: mechanism of action and therapeutic potential. Clin. Exp. Dermatol. (2002) 27:571-577.
78. SYED TA, AHMADPOUR OA, AHMAD SA, AHMAD SH: Management of female genital warts with an analog of imiquimod 2% in cream: a randomized, double-blind, placebo-controlled study. J. Dermatol. (1998) 25:429-433.
79. TROFATTER KFJ: Imiqimod in clinical practice. Eur. J. Dermatol. (1998) 8:17-19.
80. GILSON RJ, SHUPACK JL, FRIEDMANKIEN AE et al.: A randomized, controlled, safety study using imiquimod for the topical treatment of anogenital warts in HIV-infected patients. Imiquimod Study Group. AIDS (1999) 13:2397-2404.
81. HENGGE UR, BENNINGHOFF B, RUZICKA T, GOOS M: Topical immunomodulators-progress towards treating inflammation, infection, and cancer. The Lancet Infect. Dis. (2001) 1:189-198.